The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis

 

 Buy Article Permissions and Reprints

Abstract

Nonalcoholic steatohepatitis (NASH) and alcoholic hepatitis (ASH) are advanced forms of fatty liver diseases that are associated with a high morbidity and mortality worldwide. Patients with ASH or NASH are more susceptible to the progression of fibrosis and cirrhosis up to the development of hepatocellular carcinoma. Currently, there are limited medical therapies available. Accompanied by the asymptomatic disease progression, the demand for liver transplants is high. This review provides an overview about the growing evidence for a central role of NLR family pyrin domain containing 3 (NLRP3) inflammasome, a multiprotein complex that acts as a central driver of inflammation via activation of caspase 1, maturation and release of pro-inflammatory cytokines including interleukin-1β, and trigger of inflammatory pyroptotic cell death in both NASH and ASH. We also discuss potential therapeutic approaches targeting NLRP3 inflammasome and related upstream and downstream pathways to develop prognostic biomarkers and medical treatments for both liver diseases.

Publication History

Article published online:
11 June 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

• References

• 1 Estes C, Anstee QM, Arias-Loste MT. , et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 2018; 69 (04) 896-904
  CrossrefPubMedGoogle Scholar
• 2 Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-690
  CrossrefPubMedGoogle Scholar
• 3 Younossi Z, Tacke F, Arrese M. , et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019; 69 (06) 2672-2682
  CrossrefPubMedGoogle Scholar
• 4 Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94 (09) 2467-2474
  CrossrefPubMedGoogle Scholar
• 5 O'Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010; 51 (01) 307-328
  CrossrefPubMedGoogle Scholar
• 6 Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147 (04) 754-764
  CrossrefPubMedGoogle Scholar
• 7 WHO. Global status report on alcohol and health 2018. 2018 . Available at: https://apps.who.int/iris/bitstream/handle/10665/274603/9789241565639-eng.pdf . Accessed February 4, 2020
  PubMedGoogle Scholar
• 8 Dulai PS, Singh S, Patel J. , et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65 (05) 1557-1565
  CrossrefPubMedGoogle Scholar
• 9 Perazzo H, Dufour J-F. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int 2017; 37 (05) 634-647
  CrossrefPubMedGoogle Scholar
• 10 Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterology 2016; 150 (08) 1835-1848
  CrossrefPubMedGoogle Scholar
• 11 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2019
  PubMedGoogle Scholar
• 12 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. , et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149 (02) 367.e5-378.e5 , quiz e14–e15
  CrossrefPubMedGoogle Scholar
• 13 Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2018; 16 (08) 1356-1358
  CrossrefPubMedGoogle Scholar
• 14 Gao B, Ahmad MF, Nagy LE, Tsukamoto H. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol 2019; 70 (02) 249-259
  CrossrefPubMedGoogle Scholar
• 15 Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci 2016; 61 (05) 1294-1303
  CrossrefPubMedGoogle Scholar
• 16 Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332 (6037): 1519-1523
  CrossrefPubMedGoogle Scholar
• 17 Próchnicki T, Mangan MS, Latz E. Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation. F1000 Res 2016; 5: 5
  CrossrefPubMedGoogle Scholar
• 18 Guarda G, Zenger M, Yazdi AS. , et al. Differential expression of NLRP3 among hematopoietic cells. J Immunol 2011; 186 (04) 2529-2534
  CrossrefPubMedGoogle Scholar
• 19 Yazdi AS, Drexler SK, Tschopp J. The role of the inflammasome in nonmyeloid cells. J Clin Immunol 2010; 30 (05) 623-627
  CrossrefPubMedGoogle Scholar
• 20 Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol 2019; 39 (03) 277-286
  CrossrefPubMedGoogle Scholar
• 21 Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140 (06) 821-832
  CrossrefPubMedGoogle Scholar
• 22 Liu X, Zhang Z, Ruan J. , et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 2016; 535 (7610): 153-158
  CrossrefPubMedGoogle Scholar
• 23 Kayagaki N, Stowe IB, Lee BL. , et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 2015; 526 (7575): 666-671
  CrossrefPubMedGoogle Scholar
• 24 Shi J, Zhao Y, Wang K. , et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015; 526 (7575): 660-665
  CrossrefPubMedGoogle Scholar
• 25 Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011; 54 (01) 133-144
  CrossrefPubMedGoogle Scholar
• 26 Wree A, McGeough MD, Peña CA. , et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl) 2014; 92 (10) 1069-1082
  CrossrefPubMedGoogle Scholar
• 27 Mridha AR, Wree A, Robertson AAB. , et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol 2017; 66 (05) 1037-1046
  CrossrefPubMedGoogle Scholar
• 28 Blasetti Fantauzzi C, Menini S, Iacobini C. , et al. Deficiency of the purinergic receptor 2X₇ attenuates nonalcoholic steatohepatitis induced by high-fat diet: possible role of the NLRP3 inflammasome. Oxid Med Cell Longev 2017; 2017: 8962458
  CrossrefPubMedGoogle Scholar
• 29 Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest 2012; 92 (05) 713-723
  CrossrefPubMedGoogle Scholar
• 30 Dixon LJ, Flask CA, Papouchado BG, Feldstein AE, Nagy LE. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS One 2013; 8 (02) e56100
  CrossrefPubMedGoogle Scholar
• 31 Henao-Mejia J, Elinav E, Jin C. , et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482 (7384): 179-185
  CrossrefPubMedGoogle Scholar
• 32 Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47 (04) 571-579
  CrossrefPubMedGoogle Scholar
• 33 Brun P, Castagliuolo I, Di Leo V. , et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292 (02) G518-G525
  CrossrefPubMedGoogle Scholar
• 34 Nakanishi K, Kaji K, Kitade M. , et al. Exogenous administration of low-dose lipopolysaccharide potentiates liver fibrosis in a choline-deficient l-amino-acid-defined diet-induced murine steatohepatitis model. Int J Mol Sci 2019; 20 (11) 2724
  CrossrefPubMedGoogle Scholar
• 35 Xu B, Jiang M, Chu Y. , et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J Hepatol 2018; 68 (04) 773-782
  CrossrefPubMedGoogle Scholar
• 36 Lang S, Duan Y, Liu J. , et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology 2020; 71 (02) 522-538
  CrossrefPubMedGoogle Scholar
• 37 Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. J Hepatol 2019; 70 (02) 260-272
  CrossrefPubMedGoogle Scholar
• 38 Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015; 148 (01) 30-36
  CrossrefPubMedGoogle Scholar
• 39 Duan Y, Llorente C, Lang S. , et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575 (7783): 505-511
  CrossrefPubMedGoogle Scholar
• 40 Petrasek J, Bala S, Csak T. , et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122 (10) 3476-3489
  CrossrefPubMedGoogle Scholar
• 41 Petrasek J, Iracheta-Vellve A, Saha B. , et al. Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease. J Leukoc Biol 2015; 98 (02) 249-256
  CrossrefPubMedGoogle Scholar
• 42 Iracheta-Vellve A, Petrasek J, Satishchandran A. , et al. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice. J Hepatol 2015; 63 (05) 1147-1155
  CrossrefPubMedGoogle Scholar
• 43 Heo MJ, Kim TH, You JS, Blaya D, Sancho-Bru P, Kim SG. Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression. Gut 2019; 68 (04) 708-720
  CrossrefPubMedGoogle Scholar
• 44 Khanova E, Wu R, Wang W. , et al. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. Hepatology 2018; 67 (05) 1737-1753
  CrossrefPubMedGoogle Scholar
• 45 Machado MV, Michelotti GA, Xie G. , et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One 2015; 10 (05) e0127991
  CrossrefPubMedGoogle Scholar
• 46 Pihlajamäki J, Kuulasmaa T, Kaminska D. , et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol 2012; 56 (03) 663-670
  CrossrefPubMedGoogle Scholar
• 47 He K, Zhu X, Liu Y. , et al. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development. Oncotarget 2017; 8 (23) 37657-37672
  CrossrefPubMedGoogle Scholar
• 48 Zhu L, Baker SS, Gill C. , et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57 (02) 601-609
  CrossrefPubMedGoogle Scholar
• 49 Wong VW-S, Tse C-H, Lam TT-Y. , et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PLoS One 2013; 8 (04) e62885
  CrossrefPubMedGoogle Scholar
• 50 Boursier J, Mueller O, Barret M. , et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63 (03) 764-775
  CrossrefPubMedGoogle Scholar
• 51 Grant RW, Dixit VD. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol 2013; 4: 50
  CrossrefPubMedGoogle Scholar
• 52 Goossens GH, Blaak EE, Theunissen R. , et al. Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol 2012; 50 (03) 142-149
  CrossrefPubMedGoogle Scholar
• 53 Lee H-M, Kim J-J, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62 (01) 194-204
  CrossrefPubMedGoogle Scholar
• 54 Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: a current molecular and clinical perspective. Liver Res 2018; 2 (04) 161-172
  CrossrefPubMedGoogle Scholar
• 55 Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127 (05) (Suppl. 01) S87-S96
  CrossrefPubMedGoogle Scholar
• 56 Nurmi K, Virkanen J, Rajamäki K, Niemi K, Kovanen PT, Eklund KK. Ethanol inhibits activation of NLRP3 and AIM2 inflammasomes in human macrophages--a novel anti-inflammatory action of alcohol. PLoS One 2013; 8 (11) e78537-e78537
  CrossrefPubMedGoogle Scholar
• 57 Hoyt LR, Ather JL, Randall MJ. , et al. Ethanol and other short-chain alcohols inhibit NLRP3 inflammasome activation through protein tyrosine phosphatase stimulation. J Immunol 2016; 197 (04) 1322-1334
  CrossrefPubMedGoogle Scholar
• 58 Hoyt LR, Randall MJ, Ather JL. , et al. Mitochondrial ROS induced by chronic ethanol exposure promote hyper-activation of the NLRP3 inflammasome. Redox Biol 2017; 12: 883-896
  CrossrefPubMedGoogle Scholar
• 59 Le Daré B, Victoni T, Bodin A. , et al. Ethanol upregulates the P2 × 7 purinergic receptor in human macrophages. Fundam Clin Pharmacol 2019; 33 (01) 63-74
  CrossrefPubMedGoogle Scholar
• 60 Voican CS, Njiké-Nakseu M, Boujedidi H. , et al. Alcohol withdrawal alleviates adipose tissue inflammation in patients with alcoholic liver disease. Liver Int 2015; 35 (03) 967-978
  CrossrefPubMedGoogle Scholar
• 61 Peng Y, French BA, Tillman B, Morgan TR, French SW. The inflammasome in alcoholic hepatitis: its relationship with Mallory-Denk body formation. Exp Mol Pathol 2014; 97 (02) 305-313
  CrossrefPubMedGoogle Scholar
• 62 Leclercq S, Matamoros S, Cani PD. , et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A 2014; 111 (42) E4485-E4493
  CrossrefPubMedGoogle Scholar
• 63 Mutlu EA, Gillevet PM, Rangwala H. , et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302 (09) G966-G978
  CrossrefPubMedGoogle Scholar
• 64 Szabo G, Mitchell MC, McClain CJ. , et al. IL-1 receptor antagonist in combination with pentoxifylline and zinc for severe alcoholic hepatitis: a multicenter randomized double-bind placebo-controlled clinical trial. Hepatology 2018; 68: 1444A-1471A
  CrossrefPubMedGoogle Scholar
• 65 Thomas MG, Bayliss C, Bond S. , et al. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019; 9 (02) e023765
  CrossrefPubMedGoogle Scholar
• 66 Cohen SB, Proudman S, Kivitz AJ. , et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011; 13 (04) R125
  CrossrefPubMedGoogle Scholar
• 67 Thursz MR, Richardson P, Allison M. , et al; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372 (17) 1619-1628
  CrossrefPubMedGoogle Scholar
• 68 Naveau S, Chollet-Martin S, Dharancy S. , et al; Foie-Alcool group of the Association Française pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39 (05) 1390-1397
  CrossrefPubMedGoogle Scholar
• 69 Zein CO, Yerian LM, Gogate P. , et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54 (05) 1610-1619
  CrossrefPubMedGoogle Scholar
• 70 Morrison MC, Mulder P, Salic K. , et al. Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice. Int J Obes 2016; 40 (09) 1416-1423
  CrossrefPubMedGoogle Scholar
• 71 Stack JH, Beaumont K, Larsen PD. , et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 2005; 175 (04) 2630-2634
  CrossrefPubMedGoogle Scholar
• 72 Wannamaker W, Davies R, Namchuk M. , et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther 2007; 321 (02) 509-516
  CrossrefPubMedGoogle Scholar
• 73 Cabrera D, Wree A, Povero D. , et al. Andrographolide ameliorates inflammation and fibrogenesis and attenuates inflammasome activation in experimental non-alcoholic steatohepatitis. Sci Rep 2017; 7 (01) 3491
  CrossrefPubMedGoogle Scholar
• 74 Coll RC, Robertson AAB, Chae JJ. , et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21 (03) 248-255
  CrossrefPubMedGoogle Scholar
• 75 Juliana C, Fernandes-Alnemri T, Wu J. , et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem 2010; 285 (13) 9792-9802
  CrossrefPubMedGoogle Scholar
• 76 Honda H, Nagai Y, Matsunaga T. , et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J Leukoc Biol 2014; 96 (06) 1087-1100
  CrossrefPubMedGoogle Scholar
• 77 Calvente CJ, Tameda M, Johnson CD. , et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest 2019; 130: 4091-4109
  CrossrefPubMedGoogle Scholar
• 78 Jimenez Calvente C, Del Pilar H, Tameda M, Johnson CD, Feldstein AE. MicroRNA 223 3p negatively regulates the NLRP3 inflammasome in acute and chronic liver injury. Mol Ther 2019; (e-pub ahead of print) DOI: 10.1016/j.ymthe.2019.09.013.
  CrossrefPubMedGoogle Scholar
• 79 Rathkey JK, Zhao J, Liu Z. , et al. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci Immunol 2018; 3 (26) eaat2738
  CrossrefPubMedGoogle Scholar